Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Aug 2022. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5091128012 | Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 5091129016 | Leuprolide acetate 22.5 mg powder for prolonged-release suspension for injection vial | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 5091130014 | Leuprorelin acetate 22.5 mg powder for prolonged-release suspension for injection vial | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Is a | Product containing only leuprorelin in parenteral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has manufactured dose form | Powder for prolonged-release suspension for injection | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has unit of presentation | Vial | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Plays role | Antineoplastic therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has precise active ingredient | Leuprorelin acetate | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has basis of strength substance | Leuprorelin acetate | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) | Has presentation strength denominator unit | Vial | true | Inferred relationship | Existential restriction modifier | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR